Author:
Ok C Y,Hasserjian R P,Fox P S,Stingo F,Zuo Z,Young K H,Patel K,Medeiros L J,Garcia-Manero G,Wang S A
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference15 articles.
1. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I et al. (eds) Therapy-related myeloid neoplasms. International Agency for Research on Cancer (IARC): Lyon, France, 2008; pp 127–129.
2. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137–2145.
3. Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127: 197–205.
4. Bacher U, Haferlach C, Alpermann T, Schnittger S, Kern W, Haferlach T . Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma 2013; 54: 639–642.
5. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献